ALK is altered in 2.51% of central nervous system neoplasm patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ALK status and central nervous system neoplasm as inclusion criteria, 1 is early phase 1 (0 open) [3].

APOBEC1 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC1 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC2 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC2 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3A is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3A status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3B is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3B status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3C is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3C status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3D is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3D status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3F is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3F status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3G is altered in 0.71% of central nervous system neoplasm patients [2].

APOBEC3G is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC3H is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3H status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

APOBEC4 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APOBEC4 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EPCAM is altered in 0.75% of central nervous system neoplasm patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is altered in 1.37% of central nervous system neoplasm patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

ETV6 is altered in 1.82% of central nervous system neoplasm patients [2].

ETV6 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is altered in 1.24% of central nervous system neoplasm patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is altered in 1.82% of central nervous system neoplasm patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and central nervous system neoplasm as inclusion criteria, 1 is no phase specified (1 open) [3].

NTRK1 is altered in 1.74% of central nervous system neoplasm patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK2 is altered in 1.09% of central nervous system neoplasm patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK3 is altered in 1.18% of central nervous system neoplasm patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLD1 is altered in 2.44% of central nervous system neoplasm patients [2].

POLD1 is an inclusion eligibility criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain POLD1 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

POLE is altered in 3.19% of central nervous system neoplasm patients [2].

POLE is an inclusion eligibility criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain POLE status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].